Advertisement

Drugs & Aging

, Volume 7, Issue 3, pp 184–202 | Cite as

Recent Advances in Geriatric Psychopharmacology

  • Claudio A. Naranjo
  • Nathan Herrmann
  • Nicole Mittmann
  • Karen E. Bremner
Review Article Drug Therapy

Summary

Psychopharmacotherapy of the elderly must take into account the effects of age-related changes in the structure and function of the brain and various organs. In general, older people are more sensitive than young people to both the therapeutic and toxic effects of psychotropic medications, necessitating lower doses and longer dosage intervals. This holds true for the treatment of 5 major types of psychiatric illness (depression, bipolar disorder, anxiety, psychotic disorders and dementia).

The tricyclic antidepressants, although efficacious, inexpensive, and backed by 30 years of experience, are less well tolerated by the elderly than are newer antidepressants such as the selective serotonin uptake inhibitors. Problems with monoamine oxidase (MAO) inhibitors, including orthostatic hypotension and restrictions in diet and other medication use, have been overcome by the advent of reversible selective inhibitors of MAO-A, but the efficacy of these in the elderly has yet to be proven in clinical trials.

Lithium remains the mainstay for the treatment of bipolar disorder. However, careful dosing and monitoring of plasma lithium concentrations are required in the elderly due to changes in pharmacokinetics and pharmacodynamics which make older patients very sensitive to the toxic effects of this medication.

Similarly, age-related changes in the pharmacokinetics and pharmacodynamicsof the benzodiazepines, the most frequently prescribed medications for anxiety in the elderly, result in recommendations for lower doses and preferential use of those agents metabolised by conjugation (e.g. oxazepam). Buspirone, a partial serotonin 5-HT1A-agonist which is better tolerated than benzodiazepines in the elderly, may be used as an alternative.

The elderly are extremely sensitive to extrapyramidal adverse effects which the typical antipsychotics (neuroleptics) exhibit to varying extents. The selection of a suitable agent for the treatment of a psychotic disorder should be based upon the adverse effect profile of the drug and the specific symptoms and situation of the patient. The newer atypical antipsychotics, clozapine and risperidone, have yet to be well-studied in the elderly.

Dementia, exemplified by Alzheimer’s disease, is almost exclusively an illness of the elderly. Only one medication, tacrine, has been approved for its treatment, based on extensive basic research and positive results of several clinical trials. Its long term benefits have yet to be determined and it has several adverse effects, including a tendency to increase liver enzymes to the extent that the medication has to be discontinued.

Discovery and development of new medications for other psychiatric disorders in the elderly have been neglected for various research and ethical reasons which will have to be overcome if progress in geriatric psychopharmacology is to continue.

Keywords

Bipolar Disorder Adis International Limited Clozapine Risperidone Buspirone 
These keywords were added by machine and not by the authors. This process is experimental and the keywords may be updated as the learning algorithm improves.

Preview

Unable to display preview. Download preview PDF.

Unable to display preview. Download preview PDF.

References

  1. 1.
    Lebowitz BD, Cohen GD. Introduction: older Americans and their illness. In: Salzman C, editor. Clinical geriatric psychopharmacology. 2nd ed. Baltimore: Williams & Wilkins, 1992: 3–14Google Scholar
  2. 2.
    Abernethy DR. Psychotropic drugs and the aging process: pharmacokinetics and pharmacodynamics. In: Salzman C, editor. Clinical geriatric psychopharmacology. 2nd ed. Baltimore: Williams & Wilkins, 1992: 61–76Google Scholar
  3. 3.
    Jenike MA, Cremens C. Geriatric psychopharmacology. In: Jefferson JW, Griest JH, editors. Annual of drug therapy. Philadelphia: W.B. Saunders Company, 1994; 1: 125–55Google Scholar
  4. 4.
    Turner N, Scarpace PJ, Lowenthal DT. Geriatric pharmacology: basic and clinical considerations. Ann Rev Pharmacol Toxicol 1992; 32: 271–302Google Scholar
  5. 5.
    Bender AD. Effect of age on intestinal absorption: implications for drug absorption in the elderly. J Am Geriatr Soc 1968; 16: 1331–9PubMedGoogle Scholar
  6. 6.
    Borkan GA, Hults DE, Gerzof SG, et al. Age changes in body composition revealed by computed tomography. J Gerontol 1983; 38: 673–7PubMedGoogle Scholar
  7. 7.
    Hardy BG, Shulman KI, Mackenzie S, et al. Pharmacokinetics of lithium in the elderly. J Clin Psychopharmacol 1987; 7: 153–8PubMedGoogle Scholar
  8. 8.
    Greenblatt DJ, Divoll M, Abernethy DR, et al. Reduced clearance of triazolam in old age: relation to antipyrine oxidizing capacity. Br J Clin Pharmacol 1983; 15: 303–9PubMedGoogle Scholar
  9. 9.
    Greenblatt DJ, Sellers EM, Shader RI. Drug disposition in old age. N Engl J Med 1982; 306: 1081–8PubMedGoogle Scholar
  10. 10.
    Davies DF, Shock NW. Age changes in glomerular filtration rate, effective renal plasma flow, and tubular excretory capacity in adult males. J Clin Invest 1950; 29: 496–506PubMedGoogle Scholar
  11. 11.
    Sunderland T. Neurotransmission in the aging central nervous system. In: Salzman C, editor. Clinical geriatric psychopharmacology. 2nd ed. Baltimore: Williams & Wilkins, 1992: 41–59Google Scholar
  12. 12.
    Myers JK, Weissmann MM, Tischler GL, et al. Six month prevalence of psychiatric disorders in three communities. Arch Gen Psychiatry 1984; 41: 959–67PubMedGoogle Scholar
  13. 13.
    Sadavoy J, Smith I, Conn DK, et al. Depression in geriatric patients with chronic medical illness. Int J Geriatr Psychiatry 1990; 5: 187–92Google Scholar
  14. 14.
    Gurland BJ. The comparative frequency of depression in various adult age groups. J Gerontol 1976; 31: 283–92PubMedGoogle Scholar
  15. 15.
    Steingart A, Herrmann N. Major depressive disorder in the elderly: the relationship between age of onset and cognitive impairment. Int J Geriatr Psychiatry 1991; 6: 593–8Google Scholar
  16. 16.
    Brodaty H, Peters K, Boyce P, et al. Age and depression. J Affect Disord 1991; 23: 137–49PubMedGoogle Scholar
  17. 17.
    Ouslander JG. Physical illness and depression in the elderly. J Am Geriatr Soc 1982; 30: 593–9PubMedGoogle Scholar
  18. 18.
    Eastwood MR, Corbin SL. The relationship between physical illness and depression in old age. In: Murphy E, editor. Affective disorders in the elderly. Churchill Livingstone: Edinburgh 1986: 177–86Google Scholar
  19. 19.
    Salzman C, Schneider L, Lebowitz B. Antidepressant treatment of very old patients. Am J Geriatr Psychiatry 1993; 1: 21–9Google Scholar
  20. 20.
    Francis J, Martin D, Kapoor WN. A prospective study of delirium in hospitalized elderly. JAMA 1990; 263: 1097–101PubMedGoogle Scholar
  21. 21.
    Reifler BV, Teri L, Raskind M, et al. Double-blind trial of imipramine in Alzheimer’s disease with and without depression. Am J Psychiatry 1989; 146: 45–9PubMedGoogle Scholar
  22. 22.
    Alexopoulos GS. Treatment of depression. In: Salzman C, editor. Clinical geriatric psychopharmacology. 2nd ed. Baltimore: Williams & Wilkins, 1992: 137–74Google Scholar
  23. 23.
    Dunner DL. Therapeutic considerations in treating depression in the elderly. J Clin Psychiatry 1994; 12 Suppl.: 48–58Google Scholar
  24. 24.
    Preskorn SH. Recent pharmacologic advances in antidepressant therapy for the elderly. Am J Med 1993; 94 Suppl. 5A: 2S–10SPubMedGoogle Scholar
  25. 25.
    Preskorn SH. Therapeutic drug monitoring with tricyclic antidepressants: a response. J Clin Psychopharmacol 1994; 14: 277–8PubMedGoogle Scholar
  26. 26.
    Georgotas A, McCue RE, Hapworth W, et al. Comparative efficacy and safety of MAOIs versus TCAs in treating depression in the elderly. Biol Psychiatry 1986; 21: 1155–66PubMedGoogle Scholar
  27. 27.
    Georgotas A, McCue RE, Cooper TB. A placebo-controlled comparison of nortriptyline and phenelzine in maintenance therapy of elderly depressed patients. Arch Gen Psychiatry 1989; 46: 783–6PubMedGoogle Scholar
  28. 28.
    Nair NPV, Ahmed SK, Ng Ying Kin NMK, et al. Reversible and selective inhibitors of monoamine oxidase A in the treatment of depressed elderly patients. Acta Psychiatr Scand 1995; 91 Suppl. 386: 28–35Google Scholar
  29. 29.
    Nair NPV, Amin M, Holm P, et al. Moclobemide and nortriptyline in elderly depressed patients: a randomized multicentre trial against placebo. J Affect Dis 1995; 33: 1–9PubMedGoogle Scholar
  30. 30.
    Hindmarch I. A review of the psychomotor effects of paroxetine. Int Clin Psychopharmacol 1992; 6 Suppl. 4: 65–7PubMedGoogle Scholar
  31. 31.
    Brymer C, Hutner-Winograd C. Fluoxetine in elderly patients: is there cause for concern? J Am Geriatr Soc 1992; 40: 902–5PubMedGoogle Scholar
  32. 32.
    Feighner JP, Boyer WF, Tyler DL, et al. Adverse consequences of fluoxetine-MAOI combination therapy. J Clin Psychiatry 1990; 51: 222–5PubMedGoogle Scholar
  33. 33.
    Crewe HK, Lennard MS, Tucker GT, et al. The effect of selective serotonin re-uptake inhibitors on cytochrome P450 2D6 (CYP2D6) activity in human liver microsomes. Br J Clin Pharmacol 1992; 34: 262–5PubMedGoogle Scholar
  34. 34.
    Lawlor BA, Radcliffe J, Molchan SE, et al. A pilot placebo-controlled study of trazodone and buspirone in Alzheimer’s disease. Int J Geriatr Psychiatry 1994; 9: 55–9Google Scholar
  35. 35.
    Nierenberg AA, Adler LA, Peselow E, et al. Trazodone for anti-depressant-associated insomnia. Am J Psychiatry 1994; 151: 1069–72PubMedGoogle Scholar
  36. 36.
    Fontaine R, Ontiveros A, Elie R, et al. A double-blind comparison of nefazodone, imipramine, and placebo in major depression. J Clin Psychiatry 1994; 55: 234–41PubMedGoogle Scholar
  37. 37.
    Armitage R, Rush AJ, Trivedi M, et al. The effects of nefazodone on sleep architecture in depression. Neuropsychopharmacology 1994; 10: 123–7PubMedGoogle Scholar
  38. 38.
    Gurian B, Rosowsky E. Methylphenidate treatment of minor depression in very old patients. Am J Geriatr Psychiatry 1993; 1: 171–4Google Scholar
  39. 39.
    Maletta G, Winegarden T. Reversal of anorexia by methylphenidate in apathetic, severely demented nursing home patients. Am J Geriatr Psychiatry 1993; 1: 234–43Google Scholar
  40. 40.
    Rosenberg PB, Ahmed I, Hurwitz S. Methylphenidate in depressed medically ill patients. J Clin Psychiatry 1991; 52: 263–7PubMedGoogle Scholar
  41. 41.
    Chiarello RJ, Cole JO. The use of psychostimulants in general psychiatry. Arch Gen Psychiatry 1987; 44: 286–95PubMedGoogle Scholar
  42. 42.
    Young R. Geriatric mania. Clin Geriatric Med 1992; 8: 387–99Google Scholar
  43. 43.
    Eagles JW, Whalley LJ. Ageing and affective disorders: the age at first onset of affective disorders in Scotland 1969–1978. Br J Psychiatry 1985; 147: 180–7PubMedGoogle Scholar
  44. 44.
    Shulman Kl, Tohen M, Satlin A, et al. Mania compared with unipolar depression in old age. Am J Psychiatry 1992; 149: 341–5PubMedGoogle Scholar
  45. 45.
    Foster JR, Geshell WJ, Goldfarb AI. Lithium treatment in the elderly I. Clinical usage. J Gerontol 1977; 32: 299–302PubMedGoogle Scholar
  46. 46.
    Roose SP, Bone S, Haidorfer C, et al. Lithium treatment in older patients. Am J Psychiatry 1979; 136: 843–4PubMedGoogle Scholar
  47. 47.
    Murray N, Hopwood D, Balfour DJK, et al. The influence of age on lithium efficacy and side-effects in outpatients. Psychol Med 1983; 13: 53–60PubMedGoogle Scholar
  48. 48.
    Smith RE, Helms PM. Adverse effects of lithium therapy in the acutely ill elderly patient. J Clin Psychiatry 1982; 43: 94–9PubMedGoogle Scholar
  49. 49.
    Shulman KI, Mackenzie S, Hardy B. The clinical use of lithium carbonate in old age: a review. Prog Neuropsych Biol Psychiatry 1987; 11: 159–64Google Scholar
  50. 50.
    Holroyd S, Rabins PV. A retrospective chart review of lithium side effects in a geriatric outpatient population. Am J Geriatr Psychiatry 1994; 2: 346–51Google Scholar
  51. 51.
    Himmelhoch JM, Neil JF, May SJ, et al. Age, dementia, dyskinesias and lithium response. Am J Psychiatry 1980; 137: 941–5PubMedGoogle Scholar
  52. 52.
    Liptzin B. Treatment of mania. In: Salzman C, editor. Clinical geriatric psychopharmacology. 2nd ed. Baltimore: Williams &Wilkins, 1992: 175–88Google Scholar
  53. 53.
    Price LH, Heninger GR. Lithium in the treatment of mood disorders. N Engl J Med 1994; 331: 591–8PubMedGoogle Scholar
  54. 54.
    Stone K. Mania in the elderly. Br J Psychiatry 1989; 155: 220–4PubMedGoogle Scholar
  55. 55.
    Shulman KI, Post F. Bipolar affective disorder in old age. Br J Psychiatry 1980; 136: 26–32PubMedGoogle Scholar
  56. 56.
    Parker KL, Mittmann N, Shear N. Lithium augmentation in geriatric depressed outpatients: a clinical report. Int J Geriatr Psychiatry 1994; 9: 995–1002Google Scholar
  57. 57.
    Flint AJ, Rifat SL. A prospective study of lithium augmentation in antidepressant-resistant geriatric depression. J Clin Psychopharmacol 1994; 14: 353–6PubMedGoogle Scholar
  58. 58.
    Zimmer B, Rosen J, Thornton J, et al. Adjunctive lithium carbonate in nortriptyline-resistant elderly depressed patients. J Clin Psychopharmacol 1991; 11: 254–6PubMedGoogle Scholar
  59. 59.
    Conlon P. Rapid cycling mood disorder in the elderly. J Geriatr Psychiatry Neurol 1989; 2: 106–8PubMedGoogle Scholar
  60. 60.
    Elphick M. Clinical issues in the use of carbamazepine in psychiatry: a review. Psychol Med 1989; 19: 591–604PubMedGoogle Scholar
  61. 61.
    McElroy SL, Keck PE, Pope Jr HG, et al. Valproate in the treatment of bipolar disorders: literature review and clinical guidelines. J Clin Psychopharmacol 1992; 12: 42S–52SPubMedGoogle Scholar
  62. 62.
    McFarland BH, Miller MR, Straumfjord AA. Valproate use in the older manic patient. J Clin Psychiatry 1990; 51: 479–81PubMedGoogle Scholar
  63. 63.
    Risinger RC, Risby ED, Risch SC. Safety and efficacy of divalproex sodium in elderly bipolar patients. J Clin Psychiatry 1994; 55: 215PubMedGoogle Scholar
  64. 64.
    Sheikh JI. Anxiety and its disorders in old age. In: Birren JC, Sloan RB, Cohen G, editors. Handbook of mental health and aging. 2nd ed. San Diego: Academic Press, 1992: 409–32Google Scholar
  65. 65.
    Flint AJ. Epidemiology and comorbidity of anxiety disorders in the elderly. Am J Psychiatry 1994; 151(5): 640–9PubMedGoogle Scholar
  66. 66.
    Blazer DG, George L, Hughes D, et al. The epidemiology of anxiety disorders: an age comparison. In: Salzman C, Lebowitz B, editors. Anxiety disorders in the elderly. New York: Springer Publishing Company, 1991: 17–30Google Scholar
  67. 67.
    American Psychiatric Association. Diagnostic and statistical manual of mental disorders. 4th ed. (DSM-IV). Washington, D.C.: American Psychiatric Association Press, 1994Google Scholar
  68. 68.
    Greenblatt DJ, Allen MD, Locniskar A, et al. Lorazepam kinetics in the elderly. Clin Pharmacol Ther 1979; 26: 103–13PubMedGoogle Scholar
  69. 69.
    Greenblatt DJ, Allen MD, Harmatz JS, et al. Diazepam disposition determinants. Clin Pharmacol Ther 1980; 27: 301–12PubMedGoogle Scholar
  70. 70.
    Greenblatt DJ, Divoll M, Harmatz JS, et al. Oxazepam kinetics: effects of age and sex. J Exper Pharmacol 1980; 215: 86–91Google Scholar
  71. 71.
    Macklon AF, Barton M, James O, et al. The effect of age on the pharmacokinetics of diazepam. Clin Sci 1980; 59: 479–83PubMedGoogle Scholar
  72. 72.
    Greenblatt DJ, Divoll M, Abernethy DR. Alprazolam kinetics in the elderly: relation to antipyrine disposition. Arch Gen Psychiatry 1983; 40: 287–92PubMedGoogle Scholar
  73. 73.
    Shorr R, Bauwens S. Effects of patient age and physician training in choice and dose of benzodiazepine hypnotic drugs. Arch Intern Med 1990; 150: 293–5PubMedGoogle Scholar
  74. 74.
    Briggs RS, Castleden CM, Kraft CA, et al. Improved hypnotic treatment using chlormethiazole and temazepam. BMJ 1980; 1: 601–4Google Scholar
  75. 75.
    Salzman, C, Shader RI, Greenblatt DJ, et al. Long versus short half-life benzodiazepines in the elderly: kinetics and clinical effects of diazepam and oxazepam. Arch Gen Psychiatry 1983; 40: 293–7PubMedGoogle Scholar
  76. 76.
    Pomara N, Stanley B, Block R, et al. Increased sensitivity of the elderly to the central depressant effects of diazepam. J Clin Psychiatry 1985; 46: 185–7PubMedGoogle Scholar
  77. 77.
    Swift CG, Ewen JM, Clarke P, et al. Responsiveness to oral diazepam in the elderly: relationship to total and free plasma concentrations. Br J Clin Pharmacol 1985; 20: 111–8PubMedGoogle Scholar
  78. 78.
    Hinrichs JV, Ghoneim M. Diazepam, behaviour, and aging: increased sensitivity or lower baseline performance? Psychopharmacology 1987; 92: 100–5PubMedGoogle Scholar
  79. 79.
    Wilkinson GR. The effects of liver disease and aging on the disposition of diazepam, chlordiazepoxide, oxazepam and lorazepam in man. Acta Psych Scand 19978; 274: 56–74Google Scholar
  80. 80.
    Moran MG, Thompson TLI, Nies AS. Sleep disorders in the elderly. Am J Psychiatry 1988; 145: 1369–78PubMedGoogle Scholar
  81. 81.
    Weiss K. Management of anxiety and depression syndromes in the elderly. J Clin Psychiatry 1994; 55 (2 Suppl.): 5–12PubMedGoogle Scholar
  82. 82.
    Salzman C. Treatment of agitation, anxiety, and depression in dementia. Psychopharmacol Bull 1988; 24: 39–42PubMedGoogle Scholar
  83. 83.
    Greenblatt DJ, Allen MD, Shader RI, et al. Toxicity of high-dose flurazepam in the elderly. Clin Pharmacol Ther 1971; 21: 355–61Google Scholar
  84. 84.
    Greenblatt DJ, Allen MD. Toxicity of nitrazepam in the elderly: a report from the Boston Collaborative Drug Surveillance Program. Br J Clin Pharmacol 1978; 5: 407–13PubMedGoogle Scholar
  85. 85.
    Castleden CM, George CF, Marcer D, et al. Increased sensitivity to nitrazepam in old age. BMJ 1977; 1: 10–2PubMedGoogle Scholar
  86. 86.
    Pomara N, Deptual D, Medel M, et al. Effects of diazepam on recall memory: relationship between aging, dose and duration of treatment. Psychopharmacol Bull 1989; 25: 144–8PubMedGoogle Scholar
  87. 87.
    Ray WA, Griffin MR, Schaffner W, et al. Psychotropic drug use and the risk of hip fracture. N Engl J Med 1987; 316: 363–9PubMedGoogle Scholar
  88. 88.
    Nikaido AM. Ellinwood EHJ, Heatherly DG, et al. Differential CNS effects of diazepam in elderly adults. Pharmacol Biochem Behav 1987; 27: 273–81PubMedGoogle Scholar
  89. 89.
    Busto U, Sellers EM, Naranjo CA, et al. Withdrawal reaction after long-term therapeutic use of benzodiazepines. N Engl J Med 1986; 315: 854–9PubMedGoogle Scholar
  90. 90.
    Patterson JF. Triazolam syndrome in the elderly. South Med J 1987; 80: 1425–6PubMedGoogle Scholar
  91. 91.
    Kales A, Manfedi RL, Vgotas AN, et al. Rebound insomnia after only brief and intermittent use of rapidly eliminated benzodiazepines. Clin Pharmacol Ther 1991; 49: 468–76PubMedGoogle Scholar
  92. 92.
    Napoliello MJ. An interim multicentre report of 677 anxious geriatric outpatients treated with buspirone. Br J Clin Pract 1986; 40: 71–3PubMedGoogle Scholar
  93. 93.
    Robinson D, Napoliello MJ, Schenk J. The safety and usefulness of buspirone as an anxiolytic drug in elderly versus young patients. Clin Ther 1988; 10: 740–6PubMedGoogle Scholar
  94. 94.
    Singh A, Beer M. A dose range-finding study of buspirone in geriatric patients with symptoms of anxiety [letter]. J Clin Psychopharmacol 1988; 8: 67–8PubMedGoogle Scholar
  95. 95.
    Levine S, Napoliello MJ. An open study of buspirone in octogenarians with anxiety. Hum Psychopharm 1989; 4: 51–3Google Scholar
  96. 96.
    Smiley A, Moskowitz H. Effects of long-term administration of buspirone and diazepam on driver steering control. Am J Med 1986; 80: 22–9PubMedGoogle Scholar
  97. 97.
    Rickels K, Schweizer E, Csanalosi I, et al. Long-term treatment of anxiety and risk of withdrawal: prospective comparison of clorazepate and buspirone. Arch Gen Psychiatry 1988; 5: 444–50Google Scholar
  98. 98.
    Galliot J, Le Roux Y, Houghton GW, et al. Critical factors for pharmacokinetics of zopiclone in the elderly and in patients with liver and renal insufficiency. Sleep 1987; 10 Suppl. 1: 7–21Google Scholar
  99. 99.
    Delahaye C, Ferrand B, Pieddeloup C, et al. Post marketing surveillance of zopiclone: interim analysis of the first 10000 cases in a clinical study general practice. Int Clin Psychopharmacol 1990; 5 Suppl. 2: 131–8PubMedGoogle Scholar
  100. 100.
    Dehlin O, Rundgren A, Borjesson L, et al. Zopiclone to geriatric patients. A parallel double-blind dose response clinical trial of zopiclone as a hypnotic to geriatric patients — a study in a geriatric hospital. Pharmacology 1983; 27 Suppl.: 173–8PubMedGoogle Scholar
  101. 101.
    Dorian P, Sellers EM, Kaplan H, et al. Evaluation of zopiclone physical dependence liability in normal volunteers. Pharmacology 1983; 27 Suppl. 2: 228–34PubMedGoogle Scholar
  102. 102.
    Sheehan DV, Ballenger JC, Jacobsen G, et al. Treatment of endogenous anxiety with phobic, hysterical and hypochondriacal symptoms. Arch Gen Psychiatry 1980; 13: 51–9Google Scholar
  103. 103.
    Insel TR, Mueller EA, Alterman I, et al. Obsessive-compulsive disorder: a double-blind trial of clomipramine and clorgyline. Arch Gen Psychiatry 1983; 40: 605–12PubMedGoogle Scholar
  104. 104.
    Zitrin CM, Klein DF, Woerner MG, et al. Treatment of phobias I: comparison of imipramine hydrochloride and placebo. Arch Gen Psychiatry 1983; 40: 125–38PubMedGoogle Scholar
  105. 105.
    Pigott TA, Pato MT, Bernstein SE, et al. Controlled comparisons of clomipramine and fluoxetine in treatment of obsessive-compulsive disorder. Arch Gen Psychiatry 1990; 47: 926–32PubMedGoogle Scholar
  106. 106.
    Schneider L, Pollock V, Lyness S. A meta-analysis of controlled trials of neuroleptic treatment in dementia. J Am Geriatr Soc 1990; 38: 553–63PubMedGoogle Scholar
  107. 107.
    Grossberg GT, Manepalli J. The older patient with psychotic symptoms. Psychiatr Services 1995; 46: 55–9Google Scholar
  108. 108.
    Christensen R, Blazer D. Epidemiology of persecutory ideation in an elderly population in the community. Am J Psychiatry 1984; 141: 1088–91Google Scholar
  109. 109.
    Morriss RK, Rovner BW, Folstein MF, et al. Delusions in newly admitted residents of nursing homes. Am J Psychiatry 1990; 147: 299–302PubMedGoogle Scholar
  110. 110.
    Schneider LS. Efficacy of treatment for geropsychiatric patients with severe mental illness. Psychopharmacol Bull 1993; 29: 501–24PubMedGoogle Scholar
  111. 111.
    Schneider LS, Pollock VE, Lyness SA. A meta-analysis of controlled trials of neuroleptic treatment of dementia. J Am Geriatr Soc 1990; 38: 553–63PubMedGoogle Scholar
  112. 112.
    Avorn J, Dreyer P, Connelly K, et al. Use of psychoactive medications and the quality of care in rest homes. N Engl J Med 1989; 320: 227–32PubMedGoogle Scholar
  113. 113.
    Lohr JB, Jeste DV, Harris MJ, et al. Treatment of disordered behaviour. In: Salzman C, editor. Clinical geriatric psychopharmacology. Baltimore: Williams & Wilkins, 1992: 79–114Google Scholar
  114. 114.
    Kane JM, Jeste DV, Barnes TRE, et al. Tardive dyskinesia: a task force report of the American Psychiatric Association. Washington, DC.: American Psychiatric Association Press, 1992Google Scholar
  115. 115.
    Kane J, Honigfeld G, Singer J, et al. Clozapine for the treatment-resistant schizophrenic: a double-blind comparison with chlorpromazine. Arch Gen Psychiatry 1988; 45: 789–96PubMedGoogle Scholar
  116. 116.
    Salzman C, Vaccaro B, Lieff J, et al. Clozapine in older patients with psychosis and behavioral disruption. Am J Geriatr Psychiatry 1995; 3: 26–33Google Scholar
  117. 117.
    Friedman JH, Max J, Swift R. Idiopathic Parkinson’s disease in a chronic schizophrenic patient: long-term treatment with clozapine and L-DOPA. Clin Neuropharmacol 1987; 10: 470–5PubMedGoogle Scholar
  118. 118.
    Ostergaard K, Dupont E. Clozapine treatment of drug-induced psychotic symptoms in late stages of Parkinson’s disease. Acta Neurol Scand 1988; 18: 349–50Google Scholar
  119. 119.
    Pfeiffer RF, Kang J, Graber B, et al. Clozapine for psychosis in Parkinson’s disease. Mov Disord 1990; 5: 239–42PubMedGoogle Scholar
  120. 120.
    Alvir JMJ, Lieberman JA, Safferman AZ, et al. Clozapine-induced agranulocytosis. N Engl J Med 1993; 329: 162–7PubMedGoogle Scholar
  121. 121.
    Chouinard G, Jones B, Remington G, et al. A Canadian multicentre placebo-controlled study of fixed doses of risperidone and haloperidol in the treatment of chronic schizophrenic patients. J Clin Psychopharmacol 1993; 13: 25–40PubMedGoogle Scholar
  122. 122.
    Whitehouse PJ, editor. Dementia. Philadephia: F.A. Davis Company, 1993Google Scholar
  123. 123.
    Terry RD, Katzman R. Senile dementia of the Alzheimer type. Ann Neurol 1983; 14: 497–506PubMedGoogle Scholar
  124. 124.
    Rocca WA, Amaducci A, Schoenberg BS, et al. Epidemiology of clinically diagnosed Alzheimer’s disease. Ann Neurol 1986; 19: 415–24PubMedGoogle Scholar
  125. 125.
    Evans DA, Finkelstein H, Albert MS, et al. Prevalence of Alzheimer’s disease in a community population of older persons: higher than previously reported. JAMA 1989; 262: 2551–6PubMedGoogle Scholar
  126. 126.
    Hofman A, Rocca W, Brayne C, et al. The prevalence of dementia in Europe: a collaborative study of 1980–1990 findings. Int J Epidemiol 1991; 20: 736–48PubMedGoogle Scholar
  127. 127.
    Davies P, Maloney AJF. Selective loss of central cholinergic neurons in Alzheimer’s disease [letter]. Lancet 1976; 2: 1403PubMedGoogle Scholar
  128. 128.
    Chu D, Penney J, Young A, et al. Cortical GABA-B and GABA-A receptors in Alzheimer’s disease: a quantitative autoradiographic study. Neurology 1987; 37: 1454–9PubMedGoogle Scholar
  129. 129.
    Greenamyre J, Penney J, D’amoato C, et al. Dementia of the Alzheimer type: changes in the hippocampal L(3H) glutamate binding. J Neurochem 1987; 48: 543–51PubMedGoogle Scholar
  130. 130.
    Tamminga C, Foster N, Fedio P, et al. Alzheimer’s disease: low cerebral somatostatin levels correlate with impaired cognitive function and cortical metabolism. Neurology 1987; 37: 161–5PubMedGoogle Scholar
  131. 131.
    Palmer A, Stratmann G, Proctor A, et al. Possible neurotransmitter basis of behavioral changes in Alzheimer’s disease. Ann Neurol 1988; 23: 616–20PubMedGoogle Scholar
  132. 132.
    Nee L, Eldridge R, Sunderlance T, et al. Dementia of the Alzheimer-type: clinical and family study of 22 twin pairs. Neurology 1987; 37: 359–63PubMedGoogle Scholar
  133. 133.
    Spencer P, Nunn P, Hugon J, et al. Guam amyotrophic lateral sclerosis-Parkinsonism-dementia linked to a plant excitant neurotoxin. Science 1987; 237: 517–22PubMedGoogle Scholar
  134. 134.
    Aisen P, Davis K. Inflammatory mechanisms in Alzheimer’s disease: implications for therapy. Am J Psychiatry 1994; 151(8): 1005–113Google Scholar
  135. 135.
    Bowen D. The cholinergic system and excitatory amino acids in Alzheimer’s disease. Acta Neurol Scand 1990; 82 Suppl.: 15–6Google Scholar
  136. 136.
    Hunter AJ, Murray TK, Jones JA, et al. The cholinergic pharmacology of tetrahydroaminoacridine in vivo and in vitro. Br J Pharmacol 1989; 98: 79–86PubMedGoogle Scholar
  137. 137.
    Marquis JK. Pharmacological significance of acetylcholinesterase inhibition by tetrahydroaminoacridine. Biochem Pharmacol 1990; 40: 1071–6PubMedGoogle Scholar
  138. 138.
    Wagstaff AJ, McTavish D. Tacrine: a review of its pharmacodynamic and pharmacokinetic properties, and therapeutic efficacy in Alzheimer’s disease. Drugs Aging 1994; 4(6): 510–40PubMedGoogle Scholar
  139. 139.
    Eagger SA, Morant NJ, Levy R, et al. Parallel group analysis of the effects of tacrine versus placebo in Alzheimer’s disease. Dementia 1991; 2: 207–11Google Scholar
  140. 140.
    Farlow M, Gracon SI, Hershey LA, et al. A controlled trial of tacrine in Alzheimer’s disease. JAMA 1992; 268: 2523–9PubMedGoogle Scholar
  141. 141.
    Knapp MJ, Knopman DS, Solomon PR, et al. A 30-week randomized controlled trial of high-dose tacrine in patients with Alzheimer’s disease. JAMA 1994; 271: 985–91PubMedGoogle Scholar
  142. 142.
    Maltby N, Broe GA, Creasey H, et al. Efficacy of tacrine and lecithin in mild to moderate Alzheimer’s disease: double-blind trial. BMJ 1994; 308: 879–83PubMedGoogle Scholar
  143. 143.
    Summers WK, Majovski LV, Marsh GU, et al. Oral tetrahydroaminoacridine in long term treatment of senile dementia. N Engl J Med 1986; 315: 1241–5PubMedGoogle Scholar
  144. 144.
    Gauthier S, Bouchard R, Lamontagne A, et al. Tetrahydroaminoacridine-lecithin combination treatment in patients with intermediate-stage Alzheimer’s disease: results of a Canadian double-blind, crossover, multicenter study. N Engl J Med 1990; 322: 1272–6PubMedGoogle Scholar
  145. 145.
    Eagger SA, Levy R, Sahakian BJ, et al. Tacrine in Alzheimer’s disease. Lancet 1991; 337: 989–92PubMedGoogle Scholar
  146. 146.
    Wilcock GK, Surmon DJ, Scott M, et al. An evaluation of the efficacy and safety of tetrahydroaminoacridine (THA) without lecithin in the treatment of Alzheimer’s disease. Age Ageing 1993; 22: 316–24PubMedGoogle Scholar
  147. 147.
    Davis KL, Thal LJ, Gamzu ER, et al. A double-blind, placebo-controlled multicenter study of tacrine for Alzheimer’s disease. N Engl J Med 1992; 327: 1253–9PubMedGoogle Scholar
  148. 148.
    Weinstein HC, Teunisse S, van Gool WA. Tetrahydroaminoacridine and lecithin in the treatment of Alzheimer’s disease: effect on cognition, functioning in daily life, behavioral disturbances and burden experienced by the carers. J Neurol 1991; 238: 34–8PubMedGoogle Scholar
  149. 149.
    Fitten LJ, Perryman KM, Gross PL, et al. Treatment of Alzheimer’s disease with short- and long-term oral THA and lecithin: a double-blind study. Am J Psychiatry 1990; 147: 239–42PubMedGoogle Scholar
  150. 150.
    Molloy D.W, Guyatt GH, Wilson DB, et al. Effect of tetrahydroaminoacridine on cognition, function and behaviour in Alzheimer’s disease. Can Med Assoc J 1991; 144: 29–34Google Scholar
  151. 151.
    Minthon L, Gustafson L, Dalfelt G, et al. Oral tetrahydroaminoacridine treatment of Alzheimer’s disease evaluated clinically and by regional cerebral blood flow and EEG. Dementia 1993; 4: 32–42PubMedGoogle Scholar
  152. 152.
    Ahlin A, Nybac H, Junthe T, et al. Tetrahydroaminoacridine in Alzheimer’s dementia: clinical and biochemical results of a double-blind crossover trial. Hum Psychopharmacol 1991; 6: 109–18Google Scholar
  153. 153.
    Chatellier G, Lacomblenz L, Laplane D, et al. Tacrine (tetrahydroaminoacridine; THA) and lecithin in senile dementia of the Alzheimer type: a multicenter trial. BMJ 1990; 300: 495–9PubMedGoogle Scholar
  154. 154.
    Kumar V, Smith R, Reed K, et al. Plasma levels and effects of nortriptyline in geriatric depressed patients. Acta Psychiatr Scand 1987; 75: 20–8PubMedGoogle Scholar
  155. 155.
    Ahlin A, Adem A, Junthe T, et al. Pharmacokinetics of tetrahydroaminoacridine: relations to clinical and biochemical effects in Alzheimer’s patients. Int Clin Psychopharmacol 1992; 7: 29–36PubMedGoogle Scholar
  156. 156.
    Thal LK, Fuld PA, Masur DM, et al. Oral physostigmine and lecithin improves memory in Alzheimer’s disease. Ann Neurol 1983; 13: 491–6PubMedGoogle Scholar
  157. 157.
    Little A, Levy R, Chuagui-Kidd C, et al. A double-blind, placebo controlled trial of high dose lecithin in Alzheimer’s disease. J Neurol Neurosurg Psychiatry 1985; 48: 736–42PubMedGoogle Scholar
  158. 158.
    Caine E. Cholinomimetic treatment fails to improve memory disorders. N Engl J Med 1980; 303: 585–6PubMedGoogle Scholar
  159. 159.
    Tariot P, Cohen R, Welkowitz K, et al. Multiple dose arecholine infusions in Alzheimer’s disease. Arch Gen Psychiatry 1988; 45: 901–5PubMedGoogle Scholar
  160. 160.
    VanWoert MH, Heninger G, Rathey U, et al. L-dopa in senile dementia. Lancet 1970; 1: 573–4Google Scholar
  161. 161.
    Corkin S. Acetylcholine, aging and Alzheimer’s disease: implications for treatment. Trends Neurosci 1981; 4: 287–90Google Scholar
  162. 162.
    Bergman K, Brane G, Gottfries CH, et al. Alaproclate: a pharmacokinetic and biochemical study in patients with dementia of Alzheimer type. Psychopharmacology 1983; 80: 279–83PubMedGoogle Scholar
  163. 163.
    Randells PM, Marco LA, Ford DT, et al. Lithium and lecithin treatment in Alzheimer’s disease: a pilot study. J Clin Psychiatry 1984; 6: 139–47Google Scholar
  164. 164.
    Cutler NR, Haxby J, Kay AD, et al. Evaluation of zimeldine in Alzheimer’s disease: cognitive and biochemical measures. Arch Neurol 1985; 42: 744–8PubMedGoogle Scholar
  165. 165.
    Jenike MA, Albert MS, Heller H, et al. Combination therapy with lecithin and ergoloid mesylates for Alzheimer’s disease. J Clin Psychiatry 1986; 47: 249–51PubMedGoogle Scholar

Copyright information

© Adis International Limited 1995

Authors and Affiliations

  • Claudio A. Naranjo
    • 1
    • 2
  • Nathan Herrmann
    • 1
    • 2
  • Nicole Mittmann
    • 1
    • 2
  • Karen E. Bremner
    • 1
  1. 1.Sunnybrook Health Science CentreTorontoCanada
  2. 2.University of TorontoTorontoCanada

Personalised recommendations